Senate hearing raises FDA-related concerns for new rare disease drugsnews2026-02-26T19:27:02+00:00February 26th, 2026|Endpoints News|
Viatris plans to lay off up to 10% of staff, discloses Indian factory fire news2026-02-26T18:09:12+00:00February 26th, 2026|Endpoints News|
Why did my doctor push Grail’s dubious cancer test?news2026-02-26T17:09:28+00:00February 26th, 2026|Endpoints News|
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drugnews2026-02-26T16:06:55+00:00February 26th, 2026|Endpoints News|
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cashnews2026-02-26T14:58:16+00:00February 26th, 2026|Endpoints News|
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer news2026-02-26T14:52:14+00:00February 26th, 2026|Endpoints News|
Salma Health raises $80M for its clinics to treat brain healthnews2026-02-26T14:00:16+00:00February 26th, 2026|Endpoints News|
OrbiMed jumps to number one on the top 100 list of biotech venture investorsnews2026-02-26T12:00:39+00:00February 26th, 2026|Endpoints News|
Lilly’s GLP-1 pill beats Novo’s in diabetes trial, has more side effectsnews2026-02-26T11:30:10+00:00February 26th, 2026|Endpoints News|
Japan’s Asahi Kasei to buy German biotech Aicuris for $920Mnews2026-02-26T08:28:00+00:00February 26th, 2026|Endpoints News|
